CytomX Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q3 2014 to Q2 2022

Taxonomy & unit: us-gaap: USD
Description: Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary: CytomX Therapeutics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q3 2014 to Q2 2022.
CytomX Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending June 30, 2022 was $4.49M, a 31.1% increase year-over-year.
CytomX Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending June 30, 2022 was $14.6M, a 6.19% increase year-over-year.
CytomX Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $13.2M, a 11% decline from 2020.
CytomX Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2020 was $14.8M, a 22.6% decline from 2019.
CytomX Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2019 was $19.1M, a 13.2% increase from 2018.

Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)

Share-based Payment Arrangement, Expense, Quarterly (USD)

Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)

Period	TTM Value	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed
Q2 2022	$14.6M	$4.49M	+$1.07M	+31.1%	Apr 1, 2022	Jun 30, 2022	10-Q	2022-08-04
Q1 2022	$13.5M	$3.37M	+$336K	+11.1%	Jan 1, 2022	Mar 31, 2022	10-Q	2022-05-05
Q4 2021	$13.2M	$3.54M	+$125K	+3.66%	Oct 1, 2021	Dec 31, 2021	10-K/A	2023-03-27
Q3 2021	$13M	$3.16M	-$677K	-17.6%	Jul 1, 2021	Sep 30, 2021	10-Q	2021-11-04
Q2 2021	$13.7M	$3.43M	-$88K	-2.51%	Apr 1, 2021	Jun 30, 2021	10-Q	2022-08-04
Q1 2021	$13.8M	$3.03M	-$979K	-24.4%	Jan 1, 2021	Mar 31, 2021	10-Q	2022-05-05
Q4 2020	$14.8M	$3.42M	-$692K	-16.8%	Oct 1, 2020	Dec 31, 2020	10-K/A	2023-03-27
Q3 2020	$15.5M	$3.84M	-$502K	-11.6%	Jul 1, 2020	Sep 30, 2020	10-Q	2021-11-04
Q2 2020	$16M	$3.51M	-$1.94M	-35.6%	Apr 1, 2020	Jun 30, 2020	10-Q	2021-08-05
Q1 2020	$17.9M	$4.01M	-$1.18M	-22.7%	Jan 1, 2020	Mar 31, 2020	10-Q	2021-05-06
Q4 2019	$19.1M	$4.11M	-$505K	-10.9%	Oct 1, 2019	Dec 31, 2019	10-K/A	2023-03-27
Q3 2019	$19.6M	$4.34M	-$70K	-1.59%	Jul 1, 2019	Sep 30, 2019	10-Q	2020-11-05
Q2 2019	$19.7M	$5.45M	+$1.29M	+31.1%	Apr 1, 2019	Jun 30, 2019	10-Q	2020-08-06
Q1 2019	$18.4M	$5.19M	+$1.5M	+40.8%	Jan 1, 2019	Mar 31, 2019	10-Q	2020-05-07
Q4 2018	$16.9M	$4.62M	+$1.87M	+67.9%	Oct 1, 2018	Dec 31, 2018	10-K	2021-02-24
Q3 2018	$15M	$4.41M	+$1.63M	+58.7%	Jul 1, 2018	Sep 30, 2018	10-Q	2019-11-07
Q2 2018	$13.4M	$4.16M	+$1.15M	+38.3%	Apr 1, 2018	Jun 30, 2018	10-Q	2019-08-07
Q1 2018	$12.2M	$3.69M	+$941K	+34.3%	Jan 1, 2018	Mar 31, 2018	10-Q	2019-05-09
Q4 2017	$11.3M	$2.75M	+$128K	+4.88%	Oct 1, 2017	Dec 31, 2017	10-K	2020-02-27
Q3 2017	$11.2M	$2.78M	+$61K	+2.24%	Jul 1, 2017	Sep 30, 2017	10-Q	2018-11-06
Q2 2017	$11.1M	$3.01M	+$618K	+25.8%	Apr 1, 2017	Jun 30, 2017	10-Q	2018-08-08
Q1 2017	$10.5M	$2.75M	+$385K	+16.3%	Jan 1, 2017	Mar 31, 2017	10-Q	2018-05-09
Q4 2016	$10.1M	$2.62M	+$701K	+36.5%	Oct 1, 2016	Dec 31, 2016	10-K	2019-02-27
Q3 2016	$9.39M	$2.72M	+$1.38M	+102%	Jul 1, 2016	Sep 30, 2016	10-Q	2017-11-07
Q2 2016	$8.02M	$2.39M	+$1.85M	+338%	Apr 1, 2016	Jun 30, 2016	10-Q	2017-08-07
Q1 2016	$6.17M	$2.36M	+$2.19M	+1250%	Jan 1, 2016	Mar 31, 2016	10-Q	2017-05-05
Q4 2015	$3.99M	$1.92M			Oct 1, 2015	Dec 31, 2015	10-K	2018-03-07
Q3 2015		$1.34M	+$1.18M	+720%	Jul 1, 2015	Sep 30, 2015	10-Q	2016-11-03
Q2 2015		$546K			Apr 1, 2015	Jun 30, 2015	10-Q	2016-08-03
Q1 2015		$175K			Jan 1, 2015	Mar 31, 2015	10-Q	2016-05-06
Q3 2014		$164K			Jul 1, 2014	Sep 30, 2014	10-Q	2015-11-23

* An asterisk sign (*) next to the value indicates that the value is likely invalid.